Hangzhou Excelente

Hangzhou Excelente Biotech is a clinical-stage biopharmaceutical company focused on the discovery and development of innovative small molecule therapeutics for oncology and other unmet medical needs. The company specializes in targeting the ubiquitin-proteasome system (UPS) and DNA damage response (DDR) pathways to overcome drug resistance in cancer. Its lead program, EX-001, is a highly selective inhibitor of Ubiquitin-specific protease 1 (USP1) currently undergoing Phase 1 clinical evaluation for the treatment of advanced solid tumors, particularly those with BRCA mutations or homologous recombination deficiency. Backed by prominent investors like Qiming Venture Partners and Lilly Asia Ventures, Excelente Biotech aims to provide next-generation precision medicines for patients who have failed existing treatments such as PARP inhibitors. The company maintains a robust discovery pipeline leveraging its expertise in medicinal chemistry and structural biology.